Abstract

(1) Aim: Robot assisted radical cystectomy (RARC) with intacorporeal neobladder (iN) is a challenging procedure. There is a paucity of reports on RARC-iN, the extracorporeal approach being the most used. The aim of our study was to assess the learning curve of RARC-iN and to test its performance in benchmarking Pasadena consensus outcomes. (2) Material and methods: The single-institution learning curve of RARC-iN was retrospectively evaluated. Demographic, clinical and pathologic data of all patients were recorded. Indications to radical cystectomy included muscle invasive bladder cancer (pT ≥ 2) or recurrent high grade non muscle invasive bladder cancer. The cumulative sum (CUSUM) technique, one of the methods developed to monitor the performance and quality of the industrial sector, was adopted by the medical field in the 1970s to analyze learning curves for surgical procedures. The learning curve was evaluated using the following criteria: 1. operative time (OT) <5 h; 2. 24-h Hemoglobin (Hb) drop <2 g/dl; 3. severe complications (according to the Clavien classification system) <30%; 4. positive surgical margins <5%; and 5. complete lymph-node dissection defined as more than 16 nodes. Benchmarking of all five items on quintile analysis was tested, and a failure rate <20% for any outcome was set as threshold. (3) Results: the first 100 consecutive RARC-iN patients were included in the analysis. At CUSUM analysis, RARC required 20 cases to achieve a plateau in terms of operative time (defined as more than 3 consecutive procedures below 300 min). Hemoglobin drop, PSM and number of removed lymph-nodes did not change significantly along the learning curve. Overall, 41% of the patients presented at least one complication. Low-grade and high-grade complication rates were 30% and 17%, respectively. When assessing the benchmarks of all five Pasadena consensus outcomes on quintile analysis, a plateau was achieved after the first 60 cases. (4) Conclusions: RARC-iN is a challenging procedure. The potential impact of the learning curve on significant outcomes, such as high grade complications and positive surgical margins, has played a detrimental effect on its widespread adoption. According to this study, in tertiary referral centers, 60 procedures are sufficient to benchmark all outcomes defined in Pasadena RARC consensus.

Highlights

  • In 2021, 83,730 cases of bladder cancer are estimated to have occurred worldwide, with17,200 deaths [1]

  • (3) Results: the first 100 consecutive Robot assisted radical cystectomy (RARC)-intacorporeal neobladder (iN) patients were included in the analysis

  • At cumulative sum (CUSUM) analysis, RARC required 20 cases to achieve a plateau in terms of operative time

Read more

Summary

Introduction

In 2021, 83,730 cases of bladder cancer are estimated to have occurred worldwide, with17,200 deaths [1]. In 2021, 83,730 cases of bladder cancer are estimated to have occurred worldwide, with. Bladder cancer represents the sixth neoplasm () ion the world. Patients with localized disease represent 75%, and in younger patients the prevalence is even higher. The long-term survival of patients with pT1 and pTis disease explains the high prevalence and lower risk of cancer specific survival when compared to T2-T4 tumours [2]. Radical cystectomy with lymph-node dissection +/− neoadjuvant chemotherapy represents the gold standard for the treatment of recurrent BCG resistant pT1 disease and T2-T4 tumours. Early and late comorbidity is as high as 22%, and long-term complications include diurnal (8–10%) and nocturnal (20–30%) incontinence, uretero-intestinal stenosis (3–18%), metabolic disorders and B12 deficiency [3,4,5,6]

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.